Why choose TREMFYA®?
In clinical trials of patients who received TREMFYA® IV initial and SC maintenance dosing, TREMFYA® helped patients achieve:
FAST ACTING
Rapid symptom relief†
at 4 weeks
and clinical remission
at week 12.
†Symptom relief is based on fewer bowel movements and less rectal bleeding (bloody stools) observed as early as week 4.
LONG LASTING
Clinical remission at
1 year.
VISIBLE HEALING
OF THE INTESTINAL LINING
OF THE INTESTINAL LINING
Endoscopic remission
at 1 year.‡
‡Visually assessed areas may
not represent remission of the
entire colon lining.
AT 2 YEARS,
AT 2 YEARS,
many patients were in clinical remission.§
§After 1 year, patients and healthcare providers knew that TREMFYA® was used.
This may have increased results.
Results may vary.
Talk to your healthcare provider to
see if TREMFYA® is right for you.
TREMFYA® is the only IL-23 blocker for UC to offer self-administration from the start
You and your healthcare provider will discuss how you start TREMFYA® for UC:
Subcutaneous (SC) injections under the skin following training*
OR
IV infusions through
a vein in the arm
*If your healthcare provider decides that you or a caregiver may be able to give your injections of TREMFYA® at home, you should receive training on the right way to prepare and inject TREMFYA®. Do not try to inject yourself until you have been trained by your healthcare provider.
IL=interleukin.
